Patents Assigned to Inscripta, Inc.
  • Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
    Patent number: 11286471
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: March 29, 2022
    Assignee: Inscripta, Inc.
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
  • Simultaneous multiplex genome editing in yeast
    Patent number: 11279919
    Abstract: The present disclosure provides compositions of matter, methods and instruments for editing nucleic acids in live yeast cells.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: March 22, 2022
    Assignee: Inscripta, Inc.
    Inventors: Skylar Stefani, Tian Tian, Miles Gander
  • Simultaneous multiplex genome editing in yeast
    Patent number: 11274296
    Abstract: The present disclosure provides compositions of matter, methods and instruments for editing nucleic acids in live yeast cells.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: March 15, 2022
    Assignee: Inscripta, Inc.
    Inventors: Miles Gander, Tian Tian, Skylar Stefani, Patrick Westfall
  • Detection of nuclease edited sequences in automated modules and instruments
    Patent number: 11268061
    Abstract: The present disclosure provides automated modules and instruments for improved detection of nuclease genome editing of live cells. The disclosure provides improved modules—including high throughput modules—for screening cells that have been subjected to editing and identifying and selecting cells that have been properly edited.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: March 8, 2022
    Assignee: Inscripta, Inc.
    Inventors: Andrew Garst, Michael Graige, Richard Fox, Eileen Spindler, Amy Hiddessen, Phillip Belgrader, Don Masquelier, Bruce Chabansky
  • Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells via viral delivery
    Patent number: 11268088
    Abstract: This invention relates to compositions of matter, methods, modules and instruments for automated mammalian cell growth and mammalian cell transduction followed by nucleic acid-guided nuclease editing in live mammalian cells. The present compositions and methods entail viral delivery of an editing cassette to live mammalian cells such that the editing cassettes edit the cells and the edited cells continue to grow, preferably using a fully-automated end-to-end instrument to process the cells without human intervention to enhance cell processing uniformity and to maintain the integrity of the cell culture.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: March 8, 2022
    Assignee: Inscripta, Inc.
    Inventors: Phillip Belgrader, Christian Siltanen, William Watterson, Burak Dura, Bruce Chabansky, David Stumbo, Eric Smith, Jorge Bernate
  • Nucleic acid-guided nickases
    Patent number: 11268078
    Abstract: The present disclosure provides engineered nucleic acid-guided nickases and optimized scaffolds for making rational, direct edits to nucleic acids in live cells.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: March 8, 2022
    Assignee: Inscripta, Inc.
    Inventors: Juhan Kim, Benjamin Mijts
  • Curing for recursive nucleic acid-guided cell editing
    Patent number: 11254942
    Abstract: The present disclosure provides automated multi-module instrumentation and automated methods for performing recursive editing of live cells with curing of editing vectors from prior rounds of editing.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: February 22, 2022
    Assignee: Inscripta, Inc.
    Inventors: Tian Tian, Charles Johnson, Eileen Spindler
  • Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
    Patent number: 11236441
    Abstract: The present disclosure provides shuttle vectors for editing exogenous polynucleotides in heterologous live cells, as well as automated methods, modules, and multi-module cell editing instruments and systems for performing the editing methods.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: February 1, 2022
    Assignee: Inscripta, Inc.
    Inventors: Richard Fox, Daniel Held
  • Electroporation modules and instrumentation
    Patent number: 11225674
    Abstract: The present disclosure provides a sphere-packing lattice electroporation device configured for use as a stand-alone unit or in an automated multi-module cell processing environment and configured to decrease cell processing time and increase cell survival. The sphere-packing lattice utilizes lattice-forming beads that are uniform in size and that self-assemble into a crystalline-like lattice.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: January 18, 2022
    Assignee: Inscripta, Inc.
    Inventors: Christian Siltanen, Megan Basila
  • Nucleic acid-guided nucleases
    Patent number: 11220697
    Abstract: Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: January 11, 2022
    Assignee: Inscripta, Inc.
    Inventors: Andrew Garst, Ryan T. Gill, Tanya Elizabeth Warnecke Lipscomb
  • Engineered enzyme
    Patent number: 11214781
    Abstract: The present disclosure provides a novel catalytically inactive MAD7 nuclease (dMAD7) that retains the ability to bind DNA in a sequence-specific manner. The MAD7 nuclease from which the dMAD7 has been derived was isolated from Eubacterium rectale.
    Type: Grant
    Filed: July 13, 2021
    Date of Patent: January 4, 2022
    Assignee: Inscripta, Inc.
    Inventors: Juhan Kim, Benjamin Mijts
  • Automated cell processing methods, modules, instruments, and systems
    Patent number: 11203751
    Abstract: In an illustrative embodiment, automated multi-module cell editing instruments are provided to automate multiple edits into nucleic acid sequences inside one or more cells.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: December 21, 2021
    Assignee: Inscripta, Inc.
    Inventors: Jorge Bernate, Kevin Ness, Phillip Belgrader, Don Masquelier, Ryan Gill
  • Methods for increasing observed editing in bacteria
    Patent number: 11203762
    Abstract: The present disclosure relates to methods for increasing observed editing rates in the surviving bacteria cells.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: December 21, 2021
    Assignee: Inscripta, Inc.
    Inventors: Tian Tian, Eileen Spindler, Charles Johnson, Clint Davis
  • Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
    Patent number: 11198857
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: December 14, 2021
    Assignee: Inscripta, Inc.
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
  • Mad nucleases
    Patent number: 11193115
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: December 7, 2021
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • Mad nucleases
    Patent number: 11174471
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: November 16, 2021
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • Simultaneous multiplex genome editing in yeast
    Patent number: 11149260
    Abstract: The present disclosure provides compositions of matter, methods and instruments for editing nucleic acids in live yeast cells.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: October 19, 2021
    Assignee: Inscripta, Inc.
    Inventors: Skylar Stefani, Tian Tian, Miles Gander
  • Detection of nuclease edited sequences in automated modules and instruments
    Patent number: 11142740
    Abstract: The present disclosure provides automated modules and instruments for improved detection of nuclease genome editing of live cells. The disclosure provides improved modules—including high throughput modules—for screening cells that have been subjected to editing and identifying and selecting cells that have been properly edited.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: October 12, 2021
    Assignee: Inscripta, Inc.
    Inventors: Andrew Garst, Michael Graige, Richard Fox, Eileen Spindler, Amy Hiddessen, Phillip Belgrader, Don Masquelier, Bruce Chabansky
  • Simultaneous multiplex genome editing in yeast
    Patent number: 11136572
    Abstract: The present disclosure provides compositions of matter, methods and instruments for editing nucleic acids in live yeast cells.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: October 5, 2021
    Assignee: Inscripta, Inc.
    Inventors: Miles Gander, Tian Tian, Skylar Stefani, Patrick Westfall
  • Nucleic acid-guided nucleases
    Patent number: 11130970
    Abstract: Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: September 28, 2021
    Assignee: Inscripta, Inc.
    Inventors: Andrew Garst, Ryan T. Gill, Tanya Elizabeth Warnecke Lipscomb